$0.31-0.03 (-8.94%)
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
AIM in the Healthcare sector is trading at $0.31. The stock is currently near its 52-week low of $0.29, remaining 80.8% below its 200-day moving average. Technical signals show oversold RSI of 29 and bearish MACD signal, explaining why AIM maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rinta...